Since the formulation of the tumour immunosurveillance theory, considerable focus has been on enhancing the effectiveness of host antitumour immunity, particularly with respect to T cells. A cancer evades or alters the host immune response by various ways to ensure its development and survival. These include modifications of the immune cell metabolism and T cell signalling. An inhibitory cytokine milieu in the tumour microenvironment also leads to immune suppression and tumour progression within a host. This review traces the development in the field and attempts to summarize the hurdles that the approach of adoptive T cell immunotherapy against cancer faces, and discusses the conditions that must be improved to allow effective eradication of cancer.
Keywords: Cancer immunotherapy; Checkpoint inhibition; Immune activation; Immunoediting; Immunosuppression; T lymphocyte; Tumour escape.
Copyright © 2015 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.